NEXI

NexImmune, Inc. Common Stock

NEXI

Market cap $5.39M

Overview Fund Activity

Delisted

NEXI was delisted on the 11th of July, 2024.

Back to rankings

About: NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

Employees: 50

Healthcare Drug Manufacturers - General

Financial journalist opinion

NEXI Stock Alert: NexImmune Delists From Nasdaq

NexImmune (NASDAQ: NEXI ) stock is no longer trading on the Nasdaq Exchange after the company's shares were delisted on Friday morning. This saw shares of NEXI stock removed from the Nasdaq Exchange when markets opened this morning.

NEXI Stock Alert: NexImmune Delists From Nasdaq

What Is Going on With NexImmune (NEXI) Stock Today?

Embattled biotechnology firm NexImmune (NASDAQ: NEXI ) is seeing shares skyrocket on Thursday, possibly due to anticipation around a lingering business matter. Due to severe financial struggles, management has sought to dissolve the enterprise.

What Is Going on With NexImmune (NEXI) Stock Today?

NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 304,731 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.

NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.

NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidation

Shares of NexImmune (NASDAQ: NEXI ) stock are skyrocketing higher ahead of the company's special meeting of stockholders. The meeting was initially set for Dec. 21 with a record date of Nov. 6.

Dear NEXI Stock Fans, Mark Your Calendars for Jan. 18

Inexplicably, shares of embattled immunotherapy specialist NexImmune (NASDAQ: NEXI ) are skyrocketing more than 190% despite efforts to dissolve the business. An earlier attempt to vote on the liquidation and dissolution of the biotechnology enterprise failed due to a lack of quorum.

NEXI Stock Halted: What's Going on With NexImmune Shares Today?

Following a dramatic spike in shares yesterday, exchange operators at Nasdaq pulled the circuit breaker on NexImmune (NASDAQ: NEXI ). Though seemingly offering innovative solutions to disease treatment, the biotechnology firm has lost almost all its value since its initial public offering in 2021.

Here's why penny stocks like GGE, NEXI, ALT, HCDI are pumping

Penny stocks like Green Giant (GGE), Neximmune (NEXI), Altimmune (ALT), and Harbor Custom Development (HCDI) were among the best-performing companies in Wall Street on Friday. All of them jumped by more than 40% even as the Nasdaq 100 and S&P 500 indices pulled back.

Why Is NexImmune (NEXI) Stock Up 353% Today?

NexImmune (NASDAQ: NEXI ) stock is heading higher on Friday despite a lack of news from the clinical-stage biotechnology company. There are no new press releases for filings with the Securities and Exchange Commission (SEC) that help explain why NEXI stock is up today.

See News Rankings

Charts implemented using Lightweight Charts™